-+ 0.00%
-+ 0.00%
-+ 0.00%

ULTRAGENYX PHARMACEUTICAL EXEC SAYS U.S. PER PATIENT WHOLESALE ACQUISITION COST FOR FAYUVI IS SET AT $3.95 MILLION - CONF CALL

Reuters·09/17/2026 21:58:19

Please log in to view news